RC-106

• UNSPSC Description:

  RC-106 is a proteasome inhibitor (IC50: 35 μM) and Sigma receptor modulator with anticancer activity. RC-106 has antiproliferative activity against cancer cells including glioblastoma (GB) and multiple myeloma (MM)[1].

• Target Antigen:

  Proteasome; Sigma Receptor

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/rc-106.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C/C(C1=CC2=C(C=CC=C2)C=C1)=C\CN3CCC(CC3)CC4=CC=CC=C4

• Molecular Weight:

  355.52

• References & Citations:

  [1]Listro R, et al. Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents. Front Chem. 2020 Jun 30;8:495.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1346216-50-9